AlphaCentric Advisors LLC Makes New $691,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

AlphaCentric Advisors LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,333 shares of the medical research company's stock, valued at approximately $691,000.

A number of other large investors also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences during the fourth quarter worth about $30,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC increased its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $46,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Trading Up 0.0 %

EW traded up $0.04 during midday trading on Thursday, reaching $74.71. 2,517,532 shares of the company's stock traded hands, compared to its average volume of 4,465,477. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a fifty day moving average of $72.84 and a two-hundred day moving average of $69.82. The stock has a market capitalization of $44.06 billion, a price-to-earnings ratio of 10.72, a P/E/G ratio of 4.89 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock valued at $2,002,829 over the last three months. Corporate insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

EW has been the subject of a number of research reports. Daiwa America cut shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 30th. Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Robert W. Baird cut their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Finally, Barclays increased their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.